Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use

Description

This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.

Conditions

Opioid Use Disorder, Injection Related Infections, Stimulant Use Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.

Continuum of Care in Hospitalized Patients With Opioid or Stimulant Use Disorder and Infectious Complications of Drug Use - Substance Use/ID Integrated Clinic vs. TAU to Prevent Infection Related Readmission

Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use

Condition
Opioid Use Disorder
Intervention / Treatment

-

Contacts and Locations

Washington

George Washington University, Washington, District of Columbia, United States, 20052

Atlanta

Emory University, Atlanta, Georgia, United States, 30322

Baltimore

University of Maryland Baltimore, Baltimore, Maryland, United States, 21201

Morgantown

West Virginia University, Morgantown, West Virginia, United States, 26506

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age ≥ 18 years
  • 2. Admitted to study hospital (defined as hospitalized with a primary team that is not Emergency Medicine)
  • 3. Injection opioid or stimulant use in past 90 days - per patient self-report
  • 4. Active suspected or confirmed qualifying infection (see list) at time of admission.
  • * Non-vertebral osteomyelitis
  • * Vertebral osteomyelitis or discitis
  • * Epidural, subdural, or extradural abscess
  • * Intracranial or intraspinal abscess
  • * Native joint septic arthritis
  • * Prosthetic joint septic arthritis
  • * Blood stream infection (bacterial or fungal)
  • * Native valve Endocarditis
  • * Prosthetic valve endocarditis
  • * Cardiac Implantable electronic device infection
  • * Infectious pseudoaneurysm and aneurysm
  • * Infected vascular graft
  • * Septic venous thrombosis
  • * Skin and Soft tissue infection (cellulitis, skin abscess, necrotizing fasciitis)
  • * Infected skin ulcer
  • * Orthopedic hardware infection
  • * Muscle abscess/myositis
  • * Central nervous system infection (bacterial or fungal)
  • * Bacterial or fungal ophthalmologic infection
  • * Other abscess
  • * Pulmonary septic emboli
  • * Other acute bacterial or fungal infection deemed appropriate by site study team
  • * 1. Infection due to a cause other than injection drug use, per determination of a site PI.
  • 2. Inability to provide consent due to circumstance (e.g., sedated, intubated), language, or cognitive impairment.
  • 3. Unwilling to provide informed consent 4. Unable to receive potential interventions due to geography 5. On comfort measures or planned for discharge to hospice care 6. Incarcerated at the time of hospitalization 7. Other criteria at the discretion of the site investigator

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Elana Rosenthal,

Elana Rosenthal, MD, PRINCIPAL_INVESTIGATOR, University of Maryland, Baltimore

Study Record Dates

2027-10-30